Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
FURMAN, Richard R, SHARMAN, Jeff P, GHIA, Paolo, ERADAT, Herbert, ERVIN, Thomas, LAMANNA, Nicole, COIFFIER, Bertrand, PETTITT, Andrew R, SHUO MA, STILGENBAUER, Stephan, CRAMER, Paula, AIELLO, Maria, COUTRE, Steven E, JOHNSON, Dave M, MILLER, Langdon L, LI, Daniel, JAHN, Thomas M, DANSEY, Roger D, HALLEK, Michael, O'BRIEN, Susan M, CHESON, Bruce D, PAGEL, John M, HILLMEN, Peter, BARRIENTOS, Jacqueline C, ZELENETZ, Andrew D, KIPPS, Thomas J, FLINN, Ian
Published in The New England journal of medicine (13.03.2014)
Published in The New England journal of medicine (13.03.2014)
Get full text
Journal Article
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, O'Brien, Susan M
Published in The New England journal of medicine (13.03.2014)
Published in The New England journal of medicine (13.03.2014)
Get full text
Journal Article
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, Ajay K, Kahl, Brad S, de Vos, Sven, Wagner-Johnston, Nina D, Schuster, Stephen J, Jurczak, Wojciech J, Flinn, Ian W, Flowers, Christopher R, Martin, Peter, Viardot, Andreas, Blum, Kristie A, Goy, Andre H, Davies, Andrew J, Zinzani, Pier Luigi, Dreyling, Martin, Johnson, Dave, Miller, Langdon L, Holes, Leanne, Li, Daniel, Dansey, Roger D, Godfrey, Wayne R, Salles, Gilles A
Published in The New England journal of medicine (13.03.2014)
Published in The New England journal of medicine (13.03.2014)
Get full text
Journal Article
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
O'Brien, Susan M., Lamanna, Nicole, Kipps, Thomas J., Flinn, Ian, Zelenetz, Andrew D., Burger, Jan A., Keating, Michael, Mitra, Siddhartha, Holes, Leanne, Yu, Albert S., Johnson, David M., Miller, Langdon L., Kim, Yeonhee, Dansey, Roger D., Dubowy, Ronald L., Coutre, Steven E.
Published in Blood (17.12.2015)
Published in Blood (17.12.2015)
Get full text
Journal Article
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
Adusumilli, Prasad S, Cha, Edward, Cornfeld, Mark, Davis, Thomas, Diab, Adi, Dubensky, Thomas W, Evans, Elizabeth, Grogan, Jane L, Irving, Bryan A, Leidner, Rom S, Olwill, Shane A, Soon-Shiong, Patrick, Triebel, Frederic, Tuck, David, Bot, Adrian, Dansey, Roger D, Drake, Charles G, Freeman, Gordon J, Ibrahim, Ramy, Patel, Salil, Chen, Daniel S
Published in Journal for Immunotherapy of Cancer (20.06.2017)
Published in Journal for Immunotherapy of Cancer (20.06.2017)
Get full text
Journal Article
Book Review
High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future?
Baynes, R D, Dansey, R D, Klein, J L, Hamm, C, Campbell, M, Abella, E, Peters, W P
Published in Seminars in oncology (01.08.2001)
Published in Seminars in oncology (01.08.2001)
Get more information
Journal Article
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
O'Brien, Susan Mary, Lamanna, Nicole, Kipps, Thomas J., Flinn, Ian, Zelenetz, Andrew David, Burger, Jan Andreas, Holes, Leanne, Johnson, David Michael, Gu, Jessie, Dansey, Roger D., Dubowy, Ronald L., Coutre, Steven E.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)
De Vos, Sven, Sehn, Laurie Helen, Mulligan, Stephen P., Dreyling, Martin H., Rummel, Mathias J., Zinzani, Pier Luigi, Johnson, David Michael, Evans, Shelley, Dansey, Roger D., Godfrey, Wayne R., Czuczman, Myron Stefan
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL
Brown, Jennifer R., Furman, Richard R., Flinn, Ian, Coutre, Steven E., Wagner-Johnston, Nina D., Kahl, Brad S., Spurgeon, Stephen Edward Forbes, Benson, Don M., Peterman, Sissy, Johnson, David Michael, Li, Daniel, Dansey, Roger D., Jahn, Thomas Michael, Byrd, John C.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics
Saad, Fred, Smith, Matthew Raymond, Shore, Neal D., Oudard, Stephane, Miller, Kurt, Tombal, Bertrand, Sieber, Paul, Fizazi, Karim, Van Veldhuizen, Peter, Damião, Ronaldo, Marx, Gavin M., Morote, Juan, Ye, Zhishen, Dansey, Roger D., Goessl, Carsten Dietrich
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL)
Wagner-Johnston, Nina D., De Vos, Sven, Leonard, John, Sharman, Jeff Porter, Schreeder, Marshall T., Boccia, Ralph V., Barrientos, Jacqueline Claudia, Coutre, Steven E., Flinn, Ian, Boyd, Thomas E., Holes, Leanne, Johnson, David Michael, Kim, Yeonhee, Dansey, Roger D., Godfrey, Wayne R., Fowler, Nathan Hale
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)
Eradat, Herbert Aaron, Coutre, Steven E., Barrientos, Jacqueline Claudia, Rai, Kanti Roop, Farber, Charles Michael, Hillmen, Peter, Sharman, Jeff Porter, Ghia, Paolo, Coiffier, Bertrand, Walewski, Jan Andrzej, Berneman, Zwi N., O'Brien, Susan Mary, Brown, Jennifer R., Peterman, Sissy, Dansey, Roger D., Jahn, Thomas Michael, Cramer, Paula, Hallek, Michael J.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL
Barrientos, Jacqueline Claudia, Furman, Richard R., Leonard, John, Flinn, Ian, Rai, Kanti Roop, De Vos, Sven, Schreeder, Marshall T., Wagner-Johnston, Nina D., Sharman, Jeff Porter, Boyd, Thomas E., Fowler, Nathan Hale, Holes, Leanne, Johnson, David Michael, Li, Daniel, Dansey, Roger D., Jahn, Thomas Michael, Coutre, Steven E.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)
Spurgeon, Stephen Edward Forbes, Wagner-Johnston, Nina D., Furman, Richard R., Flinn, Ian, Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Leonard, John, Peterman, Sissy, Johnson, David Michael, Gu, Jessie, Dansey, Roger D., Godfrey, Wayne R., Kahl, Brad S.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
Benson, Don M., Kahl, Brad S., Furman, Richard R., Brown, Jennifer R., Wagner-Johnston, Nina D., Coutre, Steven E., Spurgeon, Stephen Edward Forbes, Byrd, John C., Leonard, John, Peterman, Sissy, Johnson, David Michael, Cho, Yoonjin, Dansey, Roger D., Godfrey, Wayne R., Flinn, Ian
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study
Leonard, John, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian, Schreeder, Marshall T., Fowler, Nathan Hale, Sharman, Jeff Porter, Boccia, Ralph V., Barrientos, Jacqueline Claudia, Rai, Kanti Roop, Boyd, Thomas E., Furman, Richard R., Holes, Leanne, Johnson, David Michael, Kim, Yeonhee, Dansey, Roger D., Godfrey, Wayne R., De Vos, Sven
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Hallek, Michael, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., O'Brien, Susan M.
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)
Leonard, John, Zinzani, Pier Luigi, Jurczak, Wojciech, Rummel, Mathias J., Salles, Gilles A., Kimby, Eva, Arkenau, Hendrik-Tobias, Davies, Andrew John, Johnson, David Michael, Evans, Shelley, Dansey, Roger D., Godfrey, Wayne R., Kahl, Brad S.
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2013)
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2013)
Get full text
Journal Article
Conference Proceeding